Literature DB >> 21515371

PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology.

M Giorgi1, G Melchiorri, V Nuccetelli, V D'Angelo, A Martorana, R Sorge, V Castelli, G Bernardi, G Sancesario.   

Abstract

Loss of dopamine neurons in experimental parkinsonism results in altered cyclic nucleotide cAMP and cGMP levels throughout the basal ganglia. Our objective was to examine whether expression of phosphodiesterase 10A (PDE10A), an isozyme presenting a unique distribution in basal ganglia, is altered after unilateral injection of 6-hydroxydopamine in the medial forebrain bundle, eliminating all midbrain dopaminergic neurons, such that cyclic nucleotide catabolism and steady state could be affected. Our study demonstrates that PDE10A mRNA levels were decreased in striatal neurons 10 weeks after 6-hydroxydopamine midbrain lesion. Such changes occurred in the striatum ipsilateral to lesion and were paralleled by decreased PDE10A protein levels and activity in striatal neurons and in striato-pallidal and striato-nigral projections. However, PDE10A protein and activity were increased while PDE10A mRNA was unchanged in the nucleus accumbens ipsilateral to the 6-hydroxydopamine midbrain lesion. Accordingly, cAMP levels were down-regulated in the nucleus accumbens, and up-regulated in the striatum ipsilateral to the lesion, but they were not significantly changed in substantia nigra and globus pallidus. Unlike cAMP, cGMP levels were decreased in all dopamine-deafferented regions. The opposite variations of cAMP steady state in striatum and nucleus accumbens are concordant and likely dependent, at least in part, on the down-regulation of PDE10A expression and activity in the former and its up-regulation in the latter. On the other hand, the down-regulation of cGMP steady state in the striato-nigral and striato-pallidal complex is not consistent with and is likely independent from the concomitant down-regulation of PDE10A. Therefore, dopamine loss inversely regulates PDE10A gene expression in the striatum and PDE10A post-transcription in the nucleus accumbens, therein differentially modulating PDE10A-dependent cAMP catabolism.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21515371     DOI: 10.1016/j.nbd.2011.04.006

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  13 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  In Vivo Characterization of Two 18F-Labeled PDE10A PET Radioligands in Nonhuman Primate Brains.

Authors:  Hui Liu; Hongjun Jin; Zonghua Luo; Xuyi Yue; Xiang Zhang; Hubert Flores; Yi Su; Joel S Perlmutter; Zhude Tu
Journal:  ACS Chem Neurosci       Date:  2018-02-19       Impact factor: 4.418

3.  Manipulation of olfactory tight junctions using papaverine to enhance intranasal delivery of gemcitabine to the brain.

Authors:  Mansi Krishan; Gary A Gudelsky; Pankaj B Desai; Mary Beth Genter
Journal:  Drug Deliv       Date:  2013-10-14       Impact factor: 6.419

4.  Human biodistribution and dosimetry of 18F-JNJ42259152, a radioligand for phosphodiesterase 10A imaging.

Authors:  Koen Van Laere; Rawaha U Ahmad; Hendra Hudyana; Sofie Celen; Kristof Dubois; Mark E Schmidt; Guy Bormans; Michel Koole
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-16       Impact factor: 9.236

5.  Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of DYT1 Dystonia.

Authors:  Vincenza D'Angelo; Valentina Castelli; Mauro Giorgi; Silvia Cardarelli; Ilaria Saverioni; Francesca Palumbo; Paola Bonsi; Antonio Pisani; Carmela Giampà; Roberto Sorge; Stefano Biagioni; Francesca R Fusco; Giuseppe Sancesario
Journal:  J Neurosci       Date:  2017-01-23       Impact factor: 6.167

6.  A novel thermoregulatory role for PDE10A in mouse and human adipocytes.

Authors:  Mohammed K Hankir; Mathias Kranz; Thorsten Gnad; Juliane Weiner; Sally Wagner; Winnie Deuther-Conrad; Felix Bronisch; Karen Steinhoff; Julia Luthardt; Nora Klöting; Swen Hesse; John P Seibyl; Osama Sabri; John T Heiker; Matthias Blüher; Alexander Pfeifer; Peter Brust; Wiebke K Fenske
Journal:  EMBO Mol Med       Date:  2016-07-01       Impact factor: 12.137

7.  The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease.

Authors:  Joanna Schwenkgrub; Malgorzata Zaremba; Ilona Joniec-Maciejak; Agnieszka Cudna; Dagmara Mirowska-Guzel; Iwona Kurkowska-Jastrzębska
Journal:  PLoS One       Date:  2017-07-28       Impact factor: 3.240

8.  Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats.

Authors:  Bart de Laat; Yvonne E Kling; Gwen Schroyen; Maarten Ooms; Jacob M Hooker; Guy Bormans; Koen Van Laere; Jenny Ceccarini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-17       Impact factor: 9.236

9.  Neuroprotective effects of tadalafil on gerbil dopaminergic neurons following cerebral ischemia.

Authors:  Kwang Taek Kim; Kyung Jin Chung; Han Sae Lee; Il Gyu Ko; Chang Ju Kim; Yong Gil Na; Khae Hawn Kim
Journal:  Neural Regen Res       Date:  2013-03-15       Impact factor: 5.135

10.  Comparison of [11C]TZ1964B and [18F]MNI659 for PET imaging brain PDE10A in nonhuman primates.

Authors:  Hui Liu; Hongjun Jin; Xuyi Yue; Junbin Han; Hao Yang; Hubert Flores; Yi Su; David Alagille; Joel S Perlmutter; Gilles Tamagnan; Zhude Tu
Journal:  Pharmacol Res Perspect       Date:  2016-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.